Albert David Limited Overview
Albert David Limited is an 88-year-old, promoter-controlled Indian branded-generics and specialty-formulation company with a niche franchise. Its flagship, Placentrex, is described by CARE Ratings as the only human-placenta-derived pharmaceutical in India developed through indigenous research, and it is protected by a process patent. The company also makes intravenous infusions (large-volume parenterals in glass and form-fill-seal plastic bottles) at Ghaziabad, oral and topical formulations and herbal products at Kolkata, and sodium stibogluconate (SSG) for kala-azar, for which it is an authorised WHO supplier. With FY26 revenue of INR 333.6 crore, it is a micro-cap at the edge of the top-100 Indian pharma companies. It is effectively debt-free and holds about INR 259 crore of cash and liquid investments, but it has stagnated operationally: revenue has fallen two years running and operating margins collapsed from about 13% to low single digits after an expensive field-force expansion. A new CEO, Amit Mahla, ex-Cipla, Sun and JB, took charge in May 2026 to engineer a turnaround.
Company's own description
In its corporate literature and on its letterhead, Albert David describes itself as "Manufacturers of Allopathic & Herbal Formulations, I.V. Infusions & Medical Disposables" under the tagline "Imagine Inspire Deliver" [BSE/NSE filings, Feb 2026 and Jul 2026]. Its stated principal business is the manufacture and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs for domestic sale and export, along with disposable syringes and needles and a range of bulk drugs [company profile reproduced by Arihant Capital and Kotak Securities, derived from AR]. The company also says it works with academic institutes, namely the Indian Institute of Chemical Biology (CSIR) and the Department of Biotechnology at Calcutta University, on outsourced research [company website via Screener].
Independent characterisation
Albert David is best understood as three businesses sharing one listed entity and one sales and distribution infrastructure:
-
Specialty branded formulations, led by Placentrex. This is a prescription franchise built on a unique biologic-derived product (human placental extract in injection and gel forms) with no direct domestic substitute. Placentrex contributed 26% of FY26 revenue (20% in FY25) according to CARE [CARE Jul-26]. Press coverage of the FY26 annual report gives "over 30%", which may reflect a different denominator or include line extensions. The top five products made up 45% of FY26 sales (39% in FY25) [CARE Jul-26], which shows high and rising concentration.
-
Hospital and institutional parenterals (IV fluids). These are large-volume parenterals made at Ghaziabad since 1981 in glass and polyethylene form-fill-seal bottles, historically with amino-acid infusions under a technical collaboration with Morishita Pharmaceuticals (an Ajinomoto subsidiary) [corporate history, Kotak/Arihant profiles]. This is a high-volume, low-price, commoditised category dominated by much larger players.
-
Herbal/OTC-adjacent and anti-infective/tropical medicine products. These include herbal brands such as Adliv (hepatoprotective) and Siotone (adaptogen), and SSG for leishmaniasis (kala-azar), supplied to WHO for use in African countries [CARE Jul-26; investyadnya/medicaldialogues profiles].
Business and revenue model
| Dimension | Characterisation | Evidence / source |
|---|---|---|
| Product vs service | Almost entirely product revenue from manufactured and traded pharmaceuticals; no material service, subscription or licensing revenue disclosed | Single segment "Pharmaceuticals" [Q4 FY26 filing] |
| Manufactured vs traded mix | Not publicly disclosed in the sources reviewed (Screener lists a "manufactured goods share" KPI behind a paywall) | — |
| Channel | Trade distribution through carrying-and-forwarding agents (CFAs) and stockists; 2,193 CFA-linked stockists at 31 Mar 2026, down from 2,338 a year earlier | [CARE Jul-26] |
| Customer types | Major pharmaceutical distributors in India (no single customer above 5% of net sales; top five clients 13% of FY26 sales vs 17% in FY25); hospitals and institutions for IV fluids; WHO (SSG); export buyers | [CARE Jul-26] |
| Promotion model | Prescription promotion through a medical-representative field force, expanded in FY25–FY26 with new divisions | [AR FY25; AR FY26] |
| Geographic focus | Strongest in eastern and northern India, with marketing offices in Mumbai, Kolkata, Lucknow and Patna; expansion into southern and western India under way | [CARE Jul-26] |
| Exports | Guyana, Philippines and Myanmar named in 2026; historically a much wider list of African, CIS and Latin American markets | [CARE Jul-26; historical profiles] |
| Value-chain position | Formulator and marketer, with some historical bulk-drug capability (the Kalyani bulk-drug unit commissioned in 1990; current status not confirmed). Imports key inputs (lactose, glass bottles, amino acids) from Finland, China, Austria and other European countries | [CARE Jul-26; corporate history] |
End-markets served
Indian Pharmaceutical Market (IPM), retail prescription: wound healing and tissue repair, orthopaedics and pain, gynaecology, hepatology, nutrition and vitamins, and anti-infectives.
Hospital and institutional market: IV fluids, parenteral nutrition and critical care.
Global public-health procurement: WHO-linked supply of SSG for visceral leishmaniasis.
Herbal and wellness: adaptogens and hepatoprotectives.
Strategy
Stated strategic themes (from annual reports)
AR FY22: focus on growing presence "organically as well as inorganically, both in the domestic and the international market", with new launches (Evacure, C3H) expected to add to revenue and profits.
AR FY25: the year was described as "challenging" and "strategic … in terms of future and stability planning". Under CEO Kunte the company "invested in creating new divisions and strengthening the field force … for future growth".
AR FY26: strengthening the product line and widening the customer base, with Placentrex as the primary growth lever; continued R&D on Placentrex bioconstituents with IIT Kharagpur; and field-force investment, which management said affected current results.
Strategic initiatives (last 24 months)
| Initiative | Timing | Description | Status / evidence |
|---|---|---|---|
| Field-force and division expansion | FY24–FY26 | More medical representatives, new divisions, and higher marketing spend in southern and western India | Implemented; caused the FY25 margin collapse; partly rationalised in FY26–Q1 FY27 (lower employee costs) [CARE Jul-26; Q1 FY27 results] |
| Placentrex scientific validation | FY26 onwards | Bioconstituent mapping with IIT Kharagpur | Ongoing [AR FY26] |
| Leadership transition | Dec 2025 – Jun 2026 | New CEO Amit Mahla, with transformation and portfolio-integration experience | Completed; strategy under the new CEO not yet articulated publicly in an investor presentation |
| Cost discipline | FY26–FY27 | Lower employee and selling and distribution costs | PBILDT margin up to 2.88% (FY26) and about 10% in Q1 FY27 [CARE Jul-26; Screener] |
| Capex | FY26 | CWIP rose to INR 21 crore | Project not specified; CARE expects no significant capex near term |
| Board strengthening | Nov 2024 – Aug 2025 | Two new independent directors | Completed |
Medium-term targets and guidance
Albert David does not publish quantitative guidance, hold earnings calls, or publish investor presentations (no transcripts identified). The only quantified external benchmarks come from CARE's rating sensitivities:
Upgrade trigger: total operating income above INR 500 crore with PBILDT margin above 15% on a sustained basis.
Downgrade triggers: liquidity below INR 100 crore; net debt / gross cash accruals above 0.25x; or debt-funded capex pushing gearing above 0.20x.
ESG and sustainability commitments
No public emissions targets or sustainability-linked commitments were identified.
Products & Services
Disclosure limitation: Albert David does not publish a complete brand-by-brand catalogue with specifications or pricing in its filings. Online pharmacy aggregators list roughly 155–162 SKUs marketed by the company (Truemeds). The catalogue below is built from filings, rating reports and historical company profiles. Pricing in India is set by trade price/MRP and, for scheduled formulations, by NPPA/DPCO ceilings; brand-level prices are not disclosed by the company.
All products fall within the single Pharmaceuticals segment and are grouped below by business line.
Specialty biologic-derived formulations
| Brand | Description | Target customer | Launch / status | Notes |
|---|---|---|---|---|
| Placentrex (injection) | Aqueous extract of human placenta; the company's flagship. CARE describes it as India's only human-placenta-based product developed through indigenous research, protected by a process patent | Orthopaedics, surgeons, dermatologists, gynaecologists and ophthalmologists (wound and tissue healing, chronic inflammatory conditions) | Long-established; launch year not disclosed | 26% of FY26 revenue [CARE Jul-26]; the leading growth lever according to the AR FY26 summary |
| Placentrex (gel) | Topical placental-extract gel for wound and burn healing | Surgeons, dermatologists, burns units, retail | Long-established | Gel form confirmed by product listings; revenue split vs injection not disclosed |
| Placentrex R&D extension | Bioconstituent mapping of placental extract with IIT Kharagpur | — | Ongoing (FY26) | Aimed at scientific validation and possible new indications [AR FY26 summary] |
Anti-infective / tropical medicine
| Brand | Description | Target customer | Notes |
|---|---|---|---|
| Sodium Stibogluconate (SSG) injection | Pentavalent antimonial for visceral leishmaniasis (kala-azar) | WHO procurement for African countries; endemic-region health systems | Albert David is an authorised WHO supplier [CARE Jul-26] |
Parenterals / IV infusions (Ghaziabad)
| Product family | Description | Target customer | Notes |
|---|---|---|---|
| Large-volume parenterals in glass bottles | IV fluids for fluid and electrolyte replacement | Hospitals, nursing homes, institutional tenders | Since 1981 [CARE Jul-26] |
| LVPs in polyethylene form-fill-seal bottles | IV fluids in blow-fill-seal plastic containers | Hospitals, institutions | FFS capacity expanded with a 1990s rights issue [corporate history] |
| Amino-acid infusions | Parenteral nutrition; technology originally from Morishita/Ajinomoto | Critical care, surgery, ICU | Collaboration since 1987 |
| Ophthalmic products | Eye preparations made at Ghaziabad | Ophthalmologists, retail | Capability confirmed [CARE Jul-26]; brands not itemised |
The specific IV fluid SKUs (for example dextrose, sodium chloride or Ringer's lactate) are standard industry products, but the company does not publish its list. Volumes and capacities are not publicly disclosed in the sources reviewed.
Herbal formulations
| Brand | Description | Target customer | Notes |
|---|---|---|---|
| Adliv | Herbal hepatoprotective | General physicians, gastroenterologists, retail | [Historical company profile] |
| Siotone (capsule) | Herbal adaptogen; historically described as the only adaptogen indicated for stress | GPs, psychiatrists, consumers | [Historical company profile] |
| Sio-range extensions (e.g. "Siooxy", planned in 2002-03) | Herbal / nutraceutical line extensions | — | Planned launch noted historically |
Nutrition, vitamins and general formulations (Kolkata and Ghaziabad)
| Brand | Description | Launch year | Verification status |
|---|---|---|---|
| Sioplex (capsules) | Multivitamin supplement | — | Listed by Truemeds as a popular product |
| Intecar (capsules) | — | 2,003 | Launch confirmed |
| Nimeril-T | — | 2,003 | Launch confirmed |
| Evict | — | 2,003 | Launch confirmed |
| Alrof-50 | — | 2,003 | Launch confirmed |
| Adlin | — | 2,003 | Launch confirmed |
| Slozin | — | 2,003 | Launch confirmed |
| Alamin-FeZ | — | 2,004 | Launch confirmed |
| Pansure | — | 2,004 | Launch confirmed |
| Evacure | — | FY2022 | Launch confirmed [AR FY22] |
| C3H | — | FY2022 | Launch confirmed [AR FY22] |
Medical disposables and bulk drugs
| Product family | Description | Status |
|---|---|---|
| Disposable syringes and needles | Single-use injection devices | Listed in the business description and letterhead ("Medical Disposables"); current scale not disclosed |
| Bulk drugs (APIs) | Range of bulk drugs, historically from the Kalyani unit | Current status of the Kalyani unit not confirmed in 2026 sources |
Recent launches (FY25–FY27)
The FY25 and FY26 annual reports refer to new divisions and "strengthening its product line and widening its clientele", but no specific new brand launches for FY25–FY27 were identified. Not publicly disclosed.
Financial Narrative
Basis: standalone, Ind AS, INR crore. FY22–FY24 figures are from Screener and the annual reports; FY25–FY26 from the Directors' Reports [AR FY25, AR FY26] and the CARE release [CARE Jul-26]. Gross profit uses StockAnalysis's definition (revenue minus cost of materials and traded goods).
Income statement
Notes:
-
The CARE vs Screener EBITDA gap in FY25–FY26 comes from classifying certain income and expense items (for example forex gains or losses and miscellaneous operating income) inside or outside operating profit. The Directors' Report EBITDA, which includes other income, is 32.61 (FY25) and 12.92 (FY26) [AR FY26].
-
FY25 PBT includes about INR 18.92 crore of non-cash fair-value gains on investments, which CARE calls "exceptional"; the equivalent figure in FY26 was INR 0.63 crore [CARE Jul-26].
-
FY22 and FY23 tax figures are derived from PBT minus PAT.
-
DPS: FY24 (INR 11.50) is derived from the INR 656.32 lakh dividend paid in FY25 ÷ 57.07 lakh shares. FY25 and FY26 (INR 5) are confirmed [AR FY25; AR FY26]. FY22 and FY23 (INR 9) are derived from Screener payout ratios (15% and 14%) and are unconfirmed; verify against the annual reports.
-
EPS sources: [AR FY25] for FY24–FY25; [AR FY26] for FY26; [Screener] for FY22–FY23 (FY23 shown as 63.38 on Screener and 63.39 on TipRanks).
Quarterly trajectory (most recent five quarters)
Sources: [Q1 FY27 results; Q4 FY26 filing; Screener; Equitybulls]. Q2 and Q3 figures are rounded from Screener.
Discrepancy: some aggregators (e.g. INDmoney) report Q4 FY26 "revenue" as INR 61.03 crore. That number is total income (revenue of 85.86 plus negative other income of -24.84), not revenue from operations.
Q1 FY27 detail: employee benefits expense fell to INR 25.55 crore from INR 28.43 crore a year earlier, while cost of materials rose to INR 18.33 crore from INR 13.25 crore, consistent with higher volumes. Tax expense was INR 3.80 crore, including a prior-year credit of INR 2.35 crore [Q1 FY27 results].
Balance sheet
Source: [Screener, standardised from AR]. Other items:
Debt split: borrowings are entirely short-term working-capital or overdraft facilities, largely overdraft drawn against 100% cash margin for interest-rate arbitrage. No term loans have been taken in six years [CARE Jul-26]. Long-term debt is therefore nil in every year.
Cash and liquidity (31 Mar 2026): cash and bank fixed deposits of INR 34.10 crore plus liquid mutual funds and bonds of INR 225.05 crore, a total of INR 259.15 crore [CARE Jul-26].
Net debt (31 Mar 2026): 30 − 259.15 = −INR 229 crore (net cash). Equivalent full liquidity data for earlier years is not available in the reviewed sources, but the investment book of INR 183–273 crore in each year implies the company has been in a net-cash position throughout.
Goodwill and intangibles: not separately material; not publicly disclosed in reviewed summaries.
Working capital: current ratio 2.11x at 31 Mar 2026 [CARE Jul-26]. Screener's working-capital days: -34 (FY22), 14 (FY23), -13 (FY24), 6 (FY25), 1 (FY26).
Retained earnings: INR 24,909.31 lakh (FY25) → INR 24,796.30 lakh (FY26) [AR FY26].
Cash flow
Source: [Screener]. Other items:
Free cash flow definition: Screener derives FCF from CFO less net capex; small definitional differences from CFO minus gross capex are possible.
Dividends paid in cash: INR 6.56 crore (FY25) and INR 2.85 crore (FY26) [AR FY26]. Earlier years are not separately verified.
Buybacks: none in FY22–FY26.
Cash accruals (gross): INR 6.48 crore (FY25) and INR 6.37 crore (FY26) [CARE Jul-26].
Key ratios
Notes:
-
ROE and ROA are computed by the analyst from Screener's balance-sheet data, using FY21 equity of INR 245 crore and FY21 assets of INR 341 crore as opening balances.
-
ROIC: with the capital base dominated by investments (about 47% of assets in FY26), operating ROIC on operating capital (net fixed assets plus CWIP plus net working capital, roughly INR 150–180 crore) was about 15–18% after tax in FY22–FY24 and negative in FY25–FY26. This is an analyst approximation and not disclosed.
-
The FY22–FY24 PBILDT/interest figures are derived from Screener operating profit divided by finance cost; FY25–FY26 are CARE's figures.
-
Net debt / EBITDA is not meaningful because the company holds net cash in every year; for FY26, net cash is about 24x CARE PBILDT.
-
CARE reports total debt to gross cash accruals of 1.90x (FY25) and 4.65x (FY26).
Commentary on trends, inflections and drivers
FY22–FY24: steady compounding with a treasury kicker. Revenue recovered strongly from the COVID-hit FY21 (INR 247 crore) to INR 362 crore by FY24. Gross margin held at 63–65%, which reflects the premium, low-competition economics of Placentrex. Operating margins were stable at about 13%. FY24 earnings were roughly doubled by INR 58 crore of other income, almost certainly mark-to-market and realised gains on the INR 273 crore investment portfolio during a buoyant Indian equity and debt market. Reported FY24 ROE of 21.7% therefore overstates core operating returns; excluding about INR 43 crore of incremental other income, PAT would have been closer to INR 42 crore and ROE about 12%.
FY25: the strategic-investment shock. Under CEO Umesh Kunte (appointed February 2023), the company invested heavily in new divisions and field-force expansion to break out of its eastern and northern stronghold [AR FY25; CARE Jul-26]. Gross margin actually improved to 66.4%, so the damage was below the gross line: operating expenses excluding COGS rose about 20% to INR 226.5 crore while revenue fell 4.6%. Operating margin collapsed from 13% to about 1%. PBT of INR 25.2 crore was flattered by an INR 18.9 crore non-cash fair-value gain. Working capital deteriorated sharply, with inventory days rising from 126 to 201, which pushed operating cash flow negative (−INR 28 crore) for the first time in more than a decade.
FY26: a partial cost reset and treasury volatility. Revenue fell another 3.5%. The second half recovered: Q3 FY26 revenue was +8.2% YoY and Q4 FY26 +14.6% YoY on revenue from operations [TheCompanyCheck quarterly series]. CARE notes PBILDT margin improving from 1.17% to 2.88% on lower employee and selling costs. However, a −INR 24.8 crore other-income swing in Q4 FY26 (investment mark-downs), higher depreciation (INR 9.8 crore, as the CWIP build-up to INR 21 crore began to be capitalised) and an INR 2.6 crore finance cost on overdrafts produced a full-year net loss of INR 1.49 crore, the company's first annual loss in the period reviewed. Management attributed the weak result to field-force investments intended to support future growth.
Q1 FY27: a genuine operating inflection, magnified by treasury. Revenue of INR 101.3 crore (+43.6% YoY) was the highest quarterly revenue in the dataset. Operating margin recovered to about 10%, and employee costs fell 10% YoY despite the higher sales, which suggests the field force has been rationalised under the new CEO. Even so, about 78% of Q1 PBT (INR 28.0 crore of other income out of INR 35.8 crore) came from the treasury book. The quality of earnings therefore remains heavily dependent on financial markets.
Structural observations.
-
Albert David is a "pharma company wrapped around a fund": investments of INR 243 crore exceed the entire market capitalisation net of operating assets.
-
Gross margins of about 65% are high for an Indian branded-generics micro-cap, but operating leverage is poor because of a sub-scale revenue base for a national field force.
-
Working capital, especially inventory, is the main operating cash-flow risk.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Pharmaceuticals segment revenue (INR Cr) | 362.46 | 345.77 | 333.60 |
YoY growth (%) | 6.1 | -4.6 | -3.5 |
Share of total revenue (%) | 100 | 100 | 100 |
Segment profit before tax (INR Cr) | 97.29 | 25.23 | 0.52 |
PBT margin (%) | 26.8 | 7.3 | 0.2 |
Operating profit before other income (INR Cr) | 47 | 3 | 6 |
Operating margin (%) | 13.0 | 0.9 | 1.7 |
Revenue by Segment (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Placentrex share of revenue (%) | 20 | 26 |
Top-5 products share of sales (%) | 39 | 45 |
Top-5 customers share of net sales (%) | 17 | 13 |
CFA-linked stockists (count, at year end) | 2,338 | 2,193 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 313.51 | 341.56 | 362.46 | 345.77 | 333.60 |
Revenue growth (%) | 26.7 | 8.9 | 6.1 | -4.6 | -3.5 |
Gross profit (INR Cr) | 198.6 | 217.5 | 236.1 | 229.5 | 219.7 |
Operating expenses excl. COGS and D&A (INR Cr) | 157.6 | 173.5 | 189.1 | 226.5 | 213.7 |
EBITDA before other income, Screener (INR Cr) | 41 | 44 | 47 | 3 | 6 |
PBILDT per CARE (INR Cr) | 41 | 44 | 47 | 4.04 | 9.62 |
Depreciation & amortisation (INR Cr) | 9 | 9 | 7 | 6.97 | 9.76 |
Operating income / EBIT before other income (INR Cr) | 32.0 | 36.2 | 40.1 | -3.8 | -4.0 |
Other income (INR Cr) | 16 | 15 | 58 | 29.58 | 7.45 |
Finance costs (INR Cr) | 0.39 | 0.34 | 0.21 | 0.41 | 2.63 |
Profit before tax (INR Cr) | 47.30 | 50.74 | 97.29 | 25.23 | 0.52 |
Tax expense (INR Cr) | 11.9 | 14.6 | 21.87 | 8.03 | 2.02 |
Net income / PAT (INR Cr) | 35.26 | 36.18 | 75.42 | 17.20 | -1.49 |
EPS basic (INR) | 61.78 | 63.39 | 132.15 | 30.14 | -2.62 |
EPS diluted (INR) | 61.78 | 63.39 | 132.15 | 30.14 | -2.62 |
Dividend per share (INR) | 9 | 9 | 11.5 | 5 | 5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 63.3 | 63.7 | 65.1 | 66.4 | 65.9 |
EBITDA margin before other income, Screener (%) | 13.1 | 12.9 | 13.0 | 0.9 | 1.7 |
PBILDT margin per CARE (%) | 13.1 | 12.9 | 13.0 | 1.17 | 2.88 |
Operating (EBIT) margin (%) | 10.2 | 10.6 | 11.1 | -1.1 | -1.2 |
PBT margin (%) | 15.1 | 14.9 | 26.8 | 7.3 | 0.2 |
Net margin (%) | 11.2 | 10.6 | 20.8 | 5.0 | -0.4 |
Effective tax rate (%) | 25.4 | 28.7 | 22.5 | 31.8 | 384.8 |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Revenue CAGR FY22–FY26 (4 years) | 1.6% | 313.51 → 333.60 |
Revenue CAGR FY21–FY26 (5 years) | 6.2% | 247.45 → 333.60 (FY21 was a COVID trough) |
Revenue CAGR FY16–FY26 (10 years) | about 0% | [Screener] |
TTM revenue (Q2 FY26–Q1 FY27) | INR 364.3 crore (+11% vs FY26) | [Screener; Q1 FY27 results] |
TTM PAT | INR 22.57 crore | [Screener; VRO] |
Share price | INR 790 | [Screener], 12 Oct 2026 |
Market capitalisation | INR 451 crore | [Screener] |
52-week high / low | INR 932 / 580 (ICICI: 903 / 579.90) | [Screener; ICICI Direct] |
All-time high / low | INR 1,753.95 / INR 263.00 | [ICICI Direct] |
Shares outstanding | 5.707 million | [Q1 FY27 results] |
Free float | About 37.8% | 100 − 62.23 |
Liquidity | Thin (example session volume about 4,300 shares on NSE) | [ICICI Direct] |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 70.57 | 87.2 | 89.9 | 85.86 | 101.34 |
Operating profit before other income (INR Cr) | -11 | 3 | 11 | 3 | 11 |
OPM (%) | -15 | 2.9 | 12 | 3.2 | 10 |
Other income (INR Cr) | 22.04 | -2 | 12 | -24.84 | 27.96 |
PBT (INR Cr) | 8.44 | -3 | 20 | -25.23 | 35.79 |
PAT (INR Cr) | 7.94 | -3.30 | 15.30 | -21.43 | 32.00 |
EPS (INR) | 13.91 | -5.78 | 26.81 | -37.56 | 56.07 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 401 | 423 | 498 | 511 | 519 |
Net fixed assets (INR Cr) | 88 | 80 | 83 | 99 | 100 |
Capital work-in-progress (INR Cr) | 1 | 3 | 7 | 2 | 21 |
Investments (INR Cr) | 183 | 193 | 273 | 260 | 243 |
Other assets incl. inventory, receivables, cash (INR Cr) | 130 | 148 | 135 | 151 | 155 |
Total borrowings (INR Cr) | 6 | 5 | 3 | 12 | 30 |
Other liabilities (INR Cr) | 116 | 106 | 112 | 107 | 98 |
Share capital (INR Cr) | 5.71 | 5.71 | 5.71 | 5.71 | 5.71 |
Reserves (INR Cr) | 274 | 306 | 377 | 387 | 386 |
Shareholders' equity (INR Cr) | 280 | 312 | 383 | 393 | 392 |
Book value per share (INR) | 490 | 546 | 671 | 688 | 686 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operations (INR Cr) | 40 | 11 | 46 | -28 | -8 |
Cash from investing (INR Cr) | -40 | -5 | -33 | 23 | -4 |
Cash from financing (INR Cr) | -2 | -6 | -8 | 0 | 12 |
Free cash flow per Screener (INR Cr) | 32 | 6 | 35 | -43 | -36 |
Implied capex (CFO minus FCF, INR Cr) | 8 | 5 | 11 | 15 | 28 |
CFO / operating profit (%) | 129 | 59 | 131 | -629 | -47 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 13.4 | 12.2 | 21.7 | 4.4 | -0.4 |
ROA on average assets (%) | 9.5 | 8.8 | 16.4 | 3.4 | -0.3 |
ROCE per Screener (%) | 17 | 17 | 28 | 6 | 1 |
Debt / equity (x) | 0.02 | 0.02 | 0.01 | 0.03 | 0.08 |
Interest coverage, (PBT + interest) / interest (x) | 122 | 150 | 464 | 62 | 1.2 |
PBILDT / interest per CARE (x) | 105 | 129 | 224 | 7.39 | 3.31 |
Asset turnover, revenue / average assets (x) | 0.85 | 0.83 | 0.79 | 0.69 | 0.65 |
Debtor days | 29 | 32 | 30 | 29 | 37 |
Inventory days | 124 | 149 | 126 | 201 | 187 |
Payable days | 96 | 95 | 98 | 118 | 104 |
Cash conversion cycle (days) | 57 | 87 | 58 | 112 | 120 |
Revenue by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue from operations, all geographies (INR Cr) | 362.46 | 345.77 | 333.60 |
Share Price & Returns
| Horizon | Stock price CAGR / return |
|---|---|
1 year | −1% |
3 years (CAGR) | −2% |
5 years (CAGR) | +5% |
10 years (CAGR) | +9% |
Valuation Multiples
| Multiple | Albert David | Peer reference (VRO, Aug 2026) |
|---|---|---|
P/E on TTM PAT of INR 22.57 crore (x) | 20.0 | Pfizer 29.3; Caplin 28.7; Eris 28.4; AstraZeneca 104.7 |
P/B (x) | 1.15 | Pfizer 4.9; Caplin 5.1; Eris 4.5 |
Enterprise value (INR Cr) | about 222 (451 market cap + 30 debt − 259 liquidity) | — |
EV / Sales TTM (x) | 0.61 | — |
EV / EBITDA TTM, operating EBITDA about INR 27 crore (x) | about 8.2 | — |
P/E excluding treasury income (x) | Not meaningful (core operations roughly breakeven on a TTM basis after tax) | — |
Dividend yield (%) | 0.63 | [Screener] |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 9 | 9 | 11.5 | 5 | 5 |
Payout ratio per Screener (%) | 15 | 14 | 9 | 17 | -192 |
Credit Ratings
| Agency | Facility | Rating | Outlook | Date |
|---|---|---|---|---|
CARE Ratings | Long-term bank facilities: cash credit INR 47.00 crore; forward contract INR 3.50 crore | CARE A | Negative | 2 Jul 2026 |
CARE Ratings | Long-term / short-term bank facilities: bank guarantee INR 11.00 crore; letter of credit INR 1.00 crore | CARE A / CARE A1 | Negative | 2 Jul 2026 |
CARE rating history | Same facilities | A (Stable) on 6 Sep 2023 and 4 Jul 2024 → A (Negative) on 25 Jun 2025 → A (Negative) on 2 Jul 2026 | — | — |
Moody's / S&P / Fitch | — | Not rated | — | — |
Analyst Conclusions
Management guidance
No quantitative guidance is published. Qualitatively, management says the FY25–FY26 field-force investments were made to support future growth, and the Board has given new CEO Amit Mahla a five-year mandate. CARE expects lower operating margins in FY27, which is why the outlook is Negative, although Q1 FY27 already exceeded that expectation.
Consensus expectations
None (no sell-side coverage).
Bull case
-
The operating inflection is real. Q1 FY27 revenue of INR 101.3 crore (+43.6% YoY) is the highest quarter in the dataset, OPM recovered to about 10%, and employee costs fell 10% YoY. If the run-rate holds, FY27 revenue could exceed INR 400 crore with high-single-digit to low-double-digit operating margins, restoring core earnings to the FY22–FY24 level of about INR 30–35 crore before treasury income.
-
Asymmetric valuation. At about INR 451 crore market cap, with about INR 259 crore of liquidity and INR 100 crore of net fixed assets, investors pay about 0.6x EV/Sales for a business with 65%+ gross margins and a unique, patent-protected flagship. A return to a 12–13% OPM at 1.5–2.0x EV/Sales would imply substantial upside.
-
Optionality from idle capital. The INR 225 crore liquid investment book could fund brand acquisitions or in-licensing that fix the scale problem. A transformation-oriented CEO from Cipla, Sun and JB raises the probability of portfolio action.
Bear case
-
Treasury-driven earnings. About 78% of Q1 FY27 PBT and the whole of TTM profitability depend on other income. Core operating EBIT was negative in FY25 and FY26. One quarter of strong sales does not establish a trend, especially after a −21% YoY quarter (Q1 FY26) made the base unusually low.
-
Structural sub-scale and concentration. At INR 334–364 crore of revenue, a national prescription-promotion model is uneconomic. The top five products are 45% of sales and Placentrex alone is 26%. Any regulatory or scientific challenge to placental extracts would be existential for profitability.
-
Governance and execution risk. Leadership churn (CEO exit, a five-month vacancy, plant and cluster heads resigning), a Negative credit outlook, negative operating cash flow for two years, a 120-day cash conversion cycle, no investor communication and only about 2% institutional ownership leave minority shareholders with low visibility and no catalyst for capital-allocation discipline.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| Mid-Nov 2026 | Q2 FY27 results | Revenue above INR 95 crore and OPM above 8% would confirm the turnaround; other-income dependence |
| Feb 2027 | Q3 FY27 results | Sustained YoY growth against a tougher base (Q3 FY26 revenue INR 89.9 crore) |
| May 2027 | FY27 audited results and dividend | Full-year core EBITDA; CFO turning positive; inventory days |
| Jun–Jul 2027 | CARE annual surveillance | Outlook revision to Stable (positive) or downgrade (negative) |
| Ongoing | CEO strategy articulation | Investor communication, portfolio rationalisation, M&A or in-licensing using cash reserves |
| Ongoing | Placentrex | IIT Kharagpur data, new indications or exports; any regulatory commentary on placental products |
| Ongoing | Capex | Purpose of the INR 21 crore CWIP; revised Schedule M compliance |
| Ongoing | Treasury | Investment-book composition and mark-to-market sensitivity |
| Ongoing | Footprint | Status of the Mandideep and Kalyani units (possible asset monetisation) |
Concluding analyst verdict
Albert David Limited is a company of two balance sheets and one problem. The first balance sheet is a fortress: about INR 259 crore of cash and liquid investments, almost no debt, an A-category credit rating and 88 years of brand heritage anchored by Placentrex, a unique, process-patented placental-extract franchise with no direct domestic competitor and gross margins near 66%. The second is an operating business that, over FY25–FY26, failed to earn its cost of capital. The FY24-era field-force expansion added cost without revenue, so revenue fell in two successive years, operating margins dropped from 13% to roughly 1–2%, working capital ballooned, and the company recorded its first annual net loss in the period reviewed. The problem linking them is scale: a business of INR 330–360 crore cannot support national prescription promotion, so treasury income, not pharmaceuticals, has been the swing factor in earnings.
The Q1 FY27 print is the most encouraging datapoint in three years. Revenue grew 43.6%, operating margin recovered to about 10% and employee costs fell. It coincides with a credible new CEO who has large-company transformation experience. At about 0.6x EV/Sales and 1.15x book, the market is pricing in permanent stagnation, which makes the risk-reward skewed favourably if the recovery proves durable.
The evidence remains thin, though: one quarter, against an abnormally weak base, with treasury gains still providing most of the profit. Disclosure is poor, institutional sponsorship is negligible, the credit outlook is Negative, and governance sits firmly with the promoter family.
Verdict: a deep-value, special-situation turnaround candidate rather than a quality compounder. It merits close monitoring through the Q2–Q3 FY27 results and CARE's 2027 review. Conviction should rise only if core operating EBITDA margins sustain above 10%, operating cash flow turns positive, and management articulates a capital-allocation plan for the idle cash, ideally inorganic scale-building in its niche therapies.
-
Employee headcount and three-year trend
-
R&D expenditure (absolute and % of revenue), patent count and patent number for Placentrex
-
Domestic vs export revenue split and any regional breakdown
-
Brand-level revenue other than Placentrex; therapeutic positioning of several historical brands
-
Itemised executive remuneration for FY26 and FY27 (A.K. Kothari, Amit Mahla)
-
Board committee composition at October 2026
-
Top-10 named shareholders
-
Current operating status of the Mandideep and Kalyani units
-
Subject and outcome of the July 2026 postal ballot
-
Contingent liabilities and any tax disputes in the annual report notes
-
Exact DPS for FY22–FY23 (derived values shown)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Arun Kumar (A.K.) Kothari | Executive Chairman (Whole-time Director) | Long-standing; re-appointed at the 86th AGM (Aug 2025) | Son of the late G.D. Kothari, founder of the G.D. Kothari Group (tea, textiles, pharma, chemicals, engineering, property) [CARE Jul-26] |
Amit Mahla | Whole-time Director & CEO (CARE calls him "Managing Director") | CEO since 12 May 2026; WTD from 19 Jun 2026 to 18 Jun 2031 | 28+ years in Indian pharma, with senior roles at Cipla, Sun Pharma and JB Pharma; experience in business transformation and portfolio integration [Board outcome; FilingReader] |
Ranadeep Bhattacharya | Chief Financial Officer | In role per AR FY25 | — |
Lalit Lohia | Company Secretary & Compliance Officer | In role at the Aug 2025 AGM | Succeeded A.B. |
Adijyoti Chattopadhyay | Corporate Head — HR | Per AR FY25 | — |
Dr. Kuntal Ganguly | Head — R&D | Per AR FY25 | — |
Santanu Bhattacharya | Plant Head, Kolkata | Per AR FY25 | — |
Chandra Bhushan Thakur | Head — Operations, Ghaziabad (per AR FY25) | A Ghaziabad operations head resigned 31 May 2026; whether this was Thakur is not confirmed | — |
Saikath Banerjee | Cluster Head | Resignation accepted 4 Jul 2026 | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Category | Notes |
|---|---|---|
Arun Kumar Kothari | Executive Chairman, Promoter | Chair and executive roles combined |
Amit Mahla | Whole-time Director & CEO | From 19 Jun 2026 |
Prabhawati Devi Kothari | Non-Executive, Promoter group | [AR FY25] |
Anand Vardhan Kothari | Non-Executive, Promoter group | [AR FY25] |
Anurag Singhi | Independent Director | [AR FY25] |
Shourya Sengupta | Independent Director | [AR FY25] |
Dr. Monjori Mitra | Independent Director (woman director) | [AR FY25] |
Naresh Pachisia | Independent Director | 14 Nov 2024 – 13 Nov 2029 |
Dr. Rajiv Anant Desai | Independent Director | 2 Aug 2025 – 1 Aug 2030 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
14 Nov 2024 | Naresh Pachisia joins as ID | Board refresh |
2 Aug 2025 | Dr. Rajiv Anant Desai joins as ID; A.K. Kothari re-appointed Executive Chairman | 86th AGM / Board meeting |
18 Dec 2025 | MD & CEO Umesh Kunte resigns | Followed two years of margin compression after his expansion strategy |
12 May 2026 | Amit Mahla becomes CEO | Turnaround mandate |
31 May 2026 | Ghaziabad operations head resigns | Plant leadership transition |
19 Jun 2026 | Mahla elevated to WTD & CEO for five years | Ratified at the 87th AGM, 6 Aug 2026 |
4 Jul 2026 | Cluster Head Saikath Banerjee resigns | Sales organisation restructuring |
Shareholding Trend
| Holder category | Sep 2025 (%) | Dec 2025 (%) | Mar 2026 (%) | Jun 2026 (%) |
|---|---|---|---|---|
Promoters and promoter group | 62.23 | 62.23 | 62.23 | 62.23 |
Foreign institutional investors | 0.60 | 0.60 | 0.58 | 0.57 |
Domestic institutional investors | 1.65 | 1.65 | 1.65 | 1.63 |
Public | 35.50 | 35.51 | 35.52 | 35.56 |
Number of shareholders | 14,666 | 13,967 | 13,555 | 13,155 |
Competitive Landscape
Competitors by Segment
| Business line | Named competitors | Positioning vs Albert David |
|---|---|---|
Placental extract / tissue repair | No direct domestic human-placenta competitor (per CARE). Indirect substitutes: growth-factor and collagen-based wound-care products, hyaluronic-acid injectables, NSAIDs and anti-inflammatories from Sun Pharma, Cipla, Mankind, Abbott India, Alkem, Intas | Albert David holds a near-monopoly in its exact molecule, but the therapy faces evidence-based scepticism and substitution by modern wound-care products |
IV fluids / LVPs | Baxter India, B. Braun Medical India, Fresenius Kabi India, Otsuka (Claris Otsuka), Aculife Healthcare (Nirma), Amanta Healthcare, Denis Chem Lab, Parenteral Drugs (India) | Albert David is a sub-scale regional player; competitors have far larger capacity and tender reach |
Herbal hepatoprotectives / adaptogens | Himalaya Wellness (Liv.52), Dabur, Charak Pharma, Zandu (Emami) | Adliv and Siotone are niche brands against dominant category leaders |
Vitamins / nutrition | Mankind, Abbott India, Sun Pharma, Alkem, Pfizer India | Highly fragmented; Albert David is a small player |
Anti-leishmanial (SSG) | Gland Pharma and other WHO-prequalified suppliers; alternatives such as liposomal amphotericin B (Gilead's AmBisome), miltefosine | Narrow, tender-driven niche |
Listed small/mid-cap branded-pharma peers (valuation reference) | Pfizer Ltd, Caplin Point Laboratories, Eris Lifesciences, AstraZeneca Pharma India, Lincoln Pharmaceuticals, Kopran, Bliss GVS | Peer valuation and return benchmarks |
Peer Comparison FY2026
| Metric | Albert David | Pfizer Ltd | Caplin Point Labs | Eris Lifesciences |
|---|---|---|---|---|
Market cap (28 Aug 2026) | 513 | 21,501 | 19,125 | 18,253 |
Revenue, TTM | 364 | 2,570 | 2,287 | 3,230 |
Net profit, TTM | 22.57 | 735.15 | 678.07 | 666.92 |
Net margin (%) | 5.97 | 26.88 | 28.10 | 20.60 |
ROE (%) | 5.75 | 19.16 | 19.73 | 18.75 |
P/E (x) | 22.74 | 29.25 | 28.74 | 28.35 |
P/B (x) | 1.21 | 4.88 | 5.08 | 4.51 |
FY26 EBITDA | 5.74 | 904.18 | 646.93 | 1,017.20 |
FY26 operating revenue | 333.60 | 2,519.65 | 1,937.47 | 2,893.64 |
FY26 EBITDA margin (%) | 1.7 | 35.9 | 33.4 | 35.2 |



